

Hepatitis C Treatment Medications & Dosing

Treatment Regimens

Genotype 1: Ledipasvir/sofosbuvir (Harvoni®) once daily for 8, 12 or 24 weeks. See Harvoni treatment options (algorithm).

Genotype 2: Sofosbuvir (Sovaldi®) once daily + ribavirin BID for 12 weeks.

Genotype 3: Sofosbuvir once daily + ribavirin BID for 24 weeks or peginterferon-based regimen for 12 weeks as noted for genotypes, 4, 5 & 6 below.

Genotype 4, 5, 6: Sofosbuvir once daily + ribavirin BID + peginterferon alfa (weekly) for 12 weeks. This regimen can also be given to persons with **Genotype 3** who are able to take peginterferon.

Harvoni® (ledipasvir/sofosbuvir)

Harvoni® is a fixed-dose combination tablet of ledipasvir 90 mg and sofosbuvir 400 mg. It is taken once daily with or without food. The dose should not be changed.

Sovaldi® (sofosbuvir)

Sovaldi is a 400 mg tablet given once a day, with or without food. The dose of Sovaldi should not be changed.

Ribavirin

Ribavirin comes in a 200 mg capsule or tablet and should be taken with food.

IMPORTANT:

Pregnancy Category X.

Please note: If creatinine clearance is below 50mL/min, ribavirin dose reduction is required. Refer to Copegus® prescribing information for full information about ribavirin dose reduction for renal impairment (Section 2.4). Consult Liver Disease & Hepatitis Specialist if any additional concerns.

Ribavirin dose is weight based (see table below) and divided between two doses (morning and evening) with food. Please note, some patients with cirrhosis and baseline anemia, may need to start at lower dose of ribavirin (600mg/day divided into 2 doses 400 mg in the am and 200 mg in the pm) and increase dose based on tolerance. Consult Liver Disease & Hepatitis Specialist if baseline Hgb is less than 12.

Weight	Ribavirin Dose
< 75 kg	600 mg qAM, 400 mg qPM (1000 mg daily)
≥ 75 kg	600 mg qAM, 600 mg qPM (1200 mg daily)

Hepatitis C Treatment Medications & Dosing

Ribavirin Dose Reduction for Anemia

When hemoglobin drops below 10g/dl on treatment, ribavirin dose reduction is recommended. See guidelines next page:

Hgb (g/dl)	Action
≥ 10	Continue at weight-based dose
< 10	Reduce ribavirin to 600 mg/day divided into 2 doses (400 mg a.m. and 200 mg p.m.)
< 8.5	Discontinue ribavirin temporarily and consult liver disease specialist. Once ribavirin has been withheld, an attempt may be made to restart at 600 mg/day and further increase to 800 mg/day. However, it is not recommended that ribavirin be increased to the original assigned dose (1000 or 1200mg/day).
Patients with history of stable cardiac disease and a decrease in Hgb of ≥ 2 g/dL during any 4-week treatment period, reduce ribavirin to 400 mg ORALLY every morning and 200 mg ORALLY every evening; discontinue if Hgb less than 12 g/dL after 4 weeks of reduced dose; if Hgb values improve, may restart at 600 mg ORALLY daily with further increase to 800 mg ORALLY daily; do not resume original assigned dose.	

Peginterferon

There are 2 pegylated interferons, peginterferon alfa 2a (Pegasys[®]) and peginterferon alfa 2b (Pegintron[®]), used for the treatment of hepatitis C. The dosing for the two medications differs.

Peginterferon alfa-2a (Pegasys[®]) dose is 180 mcg subcutaneously weekly regardless of weight.

Peginterferon alfa 2b (Pegintron[®]) dosing is weight based, as follows:

Weight	Peginterferon alfa 2b (Pegintron) dose is given subcutaneously weekly
<40 kg (88 lbs.)	50 mcg (50mcg/0.5ml)
40-50 kg (88-110 lbs.)	64 mcg (Use 0.4ml of 80 mcg/0.5ml dose)
51-60 kg (111-132 lbs.)	80 mcg (80mcg/0.5ml)
61-75 kg (133-165 lbs.)	96 mcg (Use 0.4ml of 120 mcg/0.5ml dose)
76-85 kg (166-187 lbs.)	120 mcg (120 mcg/0.5ml)
86-105 kg (187-231 lbs.)	150 mcg (150 mcg/0.5ml)
>105kg (>231 lbs)	Consider 1.5 mcg/kg but requires 2 vials. Consult Liver Disease Specialist first.

Peginterferon Dose Reduction

Consult Liver Disease Specialist and refer to specific peginterferon brand package insert for peginterferon dose reduction for decreased platelet count, neutropenia, or increased depression.

Please refer to each drug's FULL prescribing information (PI) at top of Treatment Page.